Nathan M Eshenroder, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 117 Dilworth Plaza, Poth, TX 78147 Phone: 830-393-1400 Fax: 830-393-1775 |
News Archive
Scientists from Duke-NUS Medical School and the National Centre for Infectious Diseases (NCID) found that 2003 SARS survivors who have been vaccinated with the Pfizer-BioNTech mRNA vaccine produced highly potent functional antibodies that are capable of neutralizing not only all known SARS-CoV-2 variants of concerns (VOCs) but also other animal coronaviruses that have the potential to cause human infection.
Scientists at the University of Alabama at Birmingham have identified an enzyme in the brain that may be an intriguing target for interventions against Alzheimer's disease and other dementias.
4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).
Through age 5, children born at full term with low birth weight show significantly greater risk for developing respiratory symptoms, including wheezing, coughing and pulmonary infections, according to a large longitudinal study on birth weight and development.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
› Verified 8 days ago